BeiGene
BGNE
#963
Rank
NZ$35.41 B
Marketcap
$312.09
Share price
1.02%
Change (1 day)
10.93%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -$27.43

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -$29.42. In 2022 the company made an earnings per share (EPS) of -$34.25 a decrease over its 2021 EPS that were of -$26.89.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$27.43-19.91%
2022-$34.2527.35%
2021-$26.89-19.96%
2020-$33.6020.81%
2019-$27.8131.52%
2018-$21.15417.57%
2017-$4.09-37.16%
2016-$6.50158.95%
2015-$2.51

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$1.77-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.48-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA